NextCure (NASDAQ:NXTC) Stock: Insider Adar1 Capital Management, Llc Purchases 3,662 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 3,662 shares of the business’s stock in a transaction dated Friday, November 6th. The stock was bought at an average price of $5.10 per share, for a total transaction of $18,676.20. Following the purchase, the insider owned 737,956 shares in the company, valued at approximately $3,763,575.60. This represents a 0.50% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Thursday, November 5th, Adar1 Capital Management, Llc purchased 1,024 shares of NextCure stock. The shares were bought at an average cost of $5.10 per share, for a total transaction of $5,222.40.
• On Tuesday, October 27th, Adar1 Capital Management, Llc purchased 3,553 shares of NextCure stock. The shares were bought at an average cost of $5.10 per share, for a total transaction of $18,120.30.
• On Monday, October 26th, Adar1 Capital Management, Llc purchased 1,672 shares of NextCure stock. The stock was purchased at an average price of $5.03 per share, with a total value of $8,410.16.
• On Friday, October 23rd, Adar1 Capital Management, Llc acquired 5,626 shares of NextCure stock. The stock was purchased at an average cost of $4.83 per share, with a total value of $27,173.58.

NextCure Stock Down 4.6%

Shares of NextCure stock opened at $5.98 on Wednesday. The firm has a market cap of $27.39 million, a P/E ratio of -0.69 and a beta of 1.22. NextCure, Inc. has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The business has a 50-day moving average price of $6.05 and a 200 day moving average price of $7.63.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.39).

Wall Street Analyst Weigh In

NXTC has been the topic of several research reports. HC Wainwright reissued a “buy” rating on shares of NextCure in a research report on Thursday, August 13th. Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, October 26th. Finally, Wall Street Zen raised shares of NextCure from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, NextCure presently has an average rating of “Hold” and a consensus target price of $20.00.

Institutional Trading of NextCure

A hedge fund recently raised its stake in NextCure stock. Renaissance Technologies LLC raised its position in shares of NextCure, Inc. (NASDAQ:NXTC) by 80.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,534 shares of the company’s stock after purchasing an additional 26,900 shares during the period. Renaissance Technologies LLC owned 1.68% of NextCure worth $647,000 at the end of the most recent quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells. NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.